Assembly Biosciences
Clinical-stage biopharmaceutical company focused on discovery and development of small-molecule therapeutics for serious viral and liver diseases. Pipeline and research programs emphasize antiviral mechanisms (helicase-primase inhibition, capsid assembly modulation, NTCP entry inhibition and non-nucleoside polymerase inhibition), supported by preclinical profiling, phase 1 clinical studies, GCP-based clinical operations, CRO-managed animal studies, and corporate collaboration/licensing activities. Headquartered in South San Francisco, CA.
Industries
Nr. of Employees
medium (51-250)
Assembly Biosciences
South San Francisco, California, United States
Patents
Products
Long-acting helicase-primase inhibitors for recurrent genital herpes (oral)
Orally administered, long-acting small-molecule inhibitors of the viral helicase-primase complex developed for treatment of recurrent genital herpes with clinical data supporting reductions in viral shedding and lesion rates and PK supportive of once-weekly or longer dosing.
Oral NTCP inhibitors for chronic HDV and cholestatic liver diseases
Orally bioavailable small-molecule inhibitors targeting NTCP (a hepatocyte bile acid transporter and HDV entry receptor) intended to block viral entry in HDV and to reduce hepatocyte bile acid uptake for cholestatic liver disease indications.
Next-generation capsid assembly modulators for chronic HBV
Oral small-molecule capsid assembly modulators optimized to disrupt viral replication and limit replenishment of covalently closed circular DNA (cccDNA) in HBV infection; evaluated in preclinical assays and early clinical studies.
Long-acting helicase-primase inhibitors for recurrent genital herpes (oral)
Orally administered, long-acting small-molecule inhibitors of the viral helicase-primase complex developed for treatment of recurrent genital herpes with clinical data supporting reductions in viral shedding and lesion rates and PK supportive of once-weekly or longer dosing.
Oral NTCP inhibitors for chronic HDV and cholestatic liver diseases
Orally bioavailable small-molecule inhibitors targeting NTCP (a hepatocyte bile acid transporter and HDV entry receptor) intended to block viral entry in HDV and to reduce hepatocyte bile acid uptake for cholestatic liver disease indications.
Next-generation capsid assembly modulators for chronic HBV
Oral small-molecule capsid assembly modulators optimized to disrupt viral replication and limit replenishment of covalently closed circular DNA (cccDNA) in HBV infection; evaluated in preclinical assays and early clinical studies.
Services
Collaborative R&D and licensing arrangements with academic and corporate partners, including option/license structures and cost/profit share participation.
Collaborative R&D and licensing arrangements with academic and corporate partners, including option/license structures and cost/profit share participation.
Expertise Areas
- Clinical trial management (early-phase)
- Small-molecule antiviral drug discovery
- Hepatology and liver-disease therapeutics
- Preclinical pharmacology and PK/PD
Key Technologies
- Small-molecule medicinal chemistry
- Capsid assembly modulation
- Helicase-primase inhibition
- NTCP (host entry receptor) inhibition
News & Updates
Presentation of positive Phase 1a safety, tolerability and target engagement data for an oral NTCP inhibitor at AASLD The Liver Meeting 2026.
Company presented at the H.C. Wainwright & Co. 28th Annual Global Investment Conference.
Announcement of exercise of U.S. profit-share option with a corporate partner for the HSV helicase-primase inhibitor program under an existing collaboration.
Presentation of positive Phase 1a safety, tolerability and target engagement data for an oral NTCP inhibitor at AASLD The Liver Meeting 2026.
Company presented at the H.C. Wainwright & Co. 28th Annual Global Investment Conference.
Announcement of exercise of U.S. profit-share option with a corporate partner for the HSV helicase-primase inhibitor program under an existing collaboration.